Description
For IPF, pirfenidone and nintedanib remain the only approved disease‑modifying drugs, but neither halt nor reverse fibrosis. A robust field of new therapies in IPF (and other ILDs) make up a deep pipeline with diverse mechanisms. Quantitative imaging is transforming how ILDs are measured in these clinical trials, providing stronger data with the potential to shorten trial timelines and accelerate approval.
Join us for a conversation with two leaders from National Jewish Health: Stephen Humphries, PhD, director of the Quantitative Imaging Laboratory, and pulmonologist Joshua Solomon, MD, director of the Center for Interstitial Lung Disease.
They’ll share imaging-science and clinical perspectives on the latest trends in ILD, and how automated, reproducible CT analysis can positively impact drug approval pipelines. Our guests will offer an inside perspective of the DTA (Data-Driven Texture Analysis) Fibrosis Score, a deep learning–based CT biomarker that quantifies lung fibrosis and sensitively predicts patient outcomes such as FVC decline and transplant-free survival.
Highlights
Dr. Humphries talks about the power of DTA Fibrosis Score for early detection of disease.
“Quantitative Imaging Techniques have been able to find subtle amounts of fibrotic abnormality that are not only concordant with what radiologists would identify, but also have a clinical significance in terms of shortened survival and impact on lung function.“
Watch the Full Webinar